# ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)

> **NCT05507645** · PHASE3 · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 1446 (actual)

## Conditions studied

- Ischemic Stroke
- Mild
- Thrombosis

## Interventions

- **DRUG:** Recombinant Human Prourokinase for Injection (rhPro-UK)
- **DRUG:** standard medical treatment

## Key facts

- **NCT ID:** NCT05507645
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-06-17
- **Target enrollment:** 1446 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507645, "ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05507645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*